BGBIO possible bottomWe’re not there yet, but the downtrend seems to be exhausted.
Now a break of the downtrend (black arrow) AND the resistance area of NOK 20,50/21,- needs to happen and a potential W-formation is formed (see orange scenario).
−0.3488NOK
−302.12 MNOK
389.00 KNOK
1.27 B
About BERGENBIO ASA
Sector
CEO
Martin Olin
Headquarters
Bergen
Website
Employees (FY)
29
Founded
2007
ISIN
NO0010650013
FIGI
BBG00G6BKT52
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
Just broke significant resistanceWe just broke significant resistance trend line (orange). Met first resistance at emission price at 37,50,-
The breakout has moved us closer to DNBs target at 68,-
BERGENBIO soon to break out?Price currently in a symmetrical triangle, making lower highs and higher lows. Expecting a breakout to the upside, if the price breaks out of the triangle.
Take profit 1: 45.90
Take profit 2: 51.85
Careful! if price breaks below the triangle, do not enter a trade. This stock is in an uptrend, an
BerGenBio trading plan for the next few daysThis is a trading plan based on price action. Keep in mind that BerGenBio will present updates on their current cancer treatment 25th june. This could boost the price extremely, because of the high volatility.
37.15 will be the safest price to enter a possible trade. That's why I am waiting for a
BGBIO - an intelligent bet on covidBGBIO is a biotech company with focus on cancer treatment.
Like most biotech it is extremely volatile for news, but often fluctuate between key buy and sell zones when no news are evident.
BGBIO is presenting news on their cancer treatment 25th of june.
They are currently first in line to do a fre
BGBIO / BergenBioBiotech company based i Norway/UK
Listed on OSE
BergenBio`s Bemcentinib now in
UK financed Covid-19 studym, Fast track ACCORD.
Number og study ongoing: 15
3 big:
* ACCORD Covid-19
* Bemcentinib/Keytruda combo whit Merck i NSCLC.
* AML
9 of 15 sponsored studies.
Tecnicaly potent, whit big up
BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSecQuote:
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we e
BerGenBio SMA50/200 golden cross tests breakout upon new dataABOUT BERGENBIO
OSL:BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
www.bergenbio.com
www.nordnet.no
Trinity Del
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BGBIO is 0.1634 NOK — it has increased by 0.99% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OSL exchange BERGENBIO ASA stocks are traded under the ticker BGBIO.
BERGENBIO ASA is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
BGBIO stock is 3.99% volatile and has beta coefficient of −1.52. Check out the list of the most volatile stocks — is BERGENBIO ASA there?
One year price forecast for BERGENBIO ASA has a max estimate of 2.0000 NOK and a min estimate of 0.0500 NOK.
BGBIO earnings for the last quarter are −0.01 NOK per share, whereas the estimation was −0.02 NOK resulting in a 50.00% surprise. The estimated earnings for the next quarter are −0.01 NOK per share. See more details about BERGENBIO ASA earnings.
BERGENBIO ASA revenue for the last quarter amounts to 0 NOK despite the estimated figure of 0 NOK. In the next quarter revenue is expected to reach 35.33 K NOK.
Yes, you can track BERGENBIO ASA financials in yearly and quarterly reports right on TradingView.
BGBIO stock has fallen by 2.74% compared to the previous week, the month change is a 3.43% fall, over the last year BERGENBIO ASA has showed a 69.83% decrease.
BGBIO net income for the last quarter is −27.93 M NOK, while the quarter before that showed −48.84 M NOK of net income which accounts for 42.80% change. Track more BERGENBIO ASA financial stats to get the full picture.
Today BERGENBIO ASA has the market capitalization of 435.03 M, it has decreased by 12.75% over the last week.
No, BGBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BGBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BERGENBIO ASA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 29.00 employees. See our rating of the largest employees — is BERGENBIO ASA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BERGENBIO ASA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BERGENBIO ASA stock shows the sell signal. See more of BERGENBIO ASA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on BERGENBIO ASA future price: according to them, BGBIO price has a max estimate of 2.00 NOK and a min estimate of 0.05 NOK. Read a more detailed BERGENBIO ASA forecast: see what analysts think of BERGENBIO ASA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BERGENBIO ASA EBITDA is −233.45 M NOK, and current EBITDA margin is −81.02 K%. See more stats in BERGENBIO ASA financial statements.